Owing to the dysregulation of protein kinase activity in many diseases including cancer, this
enzyme family has become one of the most important drug targets in the 21 st century. There …

Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …

The development of interventions to slow or halt the progression of Parkinson's disease
remains a priority for patients and researchers alike. To date, no agents have been shown to …

Abstract Proteolysis Targeting Chimera (PROTAC) technology is a rapidly emerging
alternative therapeutic strategy with the potential to address many of the challenges …

We describe a chemical proteomics approach to profile the interaction of small molecules
with hundreds of endogenously expressed protein kinases and purine-binding proteins. This …

Neurodegeneration in patients with Parkinson's disease is correlated with the occurrence of
Lewy bodies—intracellular inclusions that contain aggregates of the intrinsically disordered …

Chronic myeloid leukemia (CML) has been regarded as the paradigmatic example of a
malignancy defined by a unique molecular event, the BCR-ABL1 oncogene. Decades of …

The Abelson (ABL) family of nonreceptor tyrosine kinases, ABL1 and ABL2, transduces
diverse extracellular signals to protein networks that control proliferation, survival, migration …

Background Weak intermolecular interactions such as hydrogen bonding and hydrophobic
interactions are key players in stabilizing energetically-favored ligands, in an open …

Clinical development of BTK kinase inhibitors for treating autoimmune diseases has lagged
behind development of these drugs for treating cancers, due in part from concerns over the …